Form 10-KT - Transition reports [Rule 13a-10 or 15d-10]:
SEC Accession No. 0000950134-02-002358
Filing Date
2002-03-20
Accepted
2002-03-20 00:00:00
Documents
5
Period of Report
2001-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K TRANSITION REPORT FOR DECEMBER 31, 2001 d94952e10-kt.txt 10-KT 300484
3 CERTIFICATE OF INCORPORATION d94952ex3-1a.txt EX-3.1(A) 11287
4 AMENDMENT TO CERTIFICATE OF INCORPORATION d94952ex3-1b.txt EX-3.1(B) 3623
5 CONSENT OF ARTHUR ANDERSEN LLP d94952ex23-1.txt EX-23.1 528
6 LETTER RE: ARTHUR ANDERSEN LLP REPRESENTATIONS d94952ex99-1.txt EX-99.1 1561
  Complete submission text file 0000950134-02-002358.txt   319532
Mailing Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701
Business Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701 5127089310
INTROGEN THERAPEUTICS INC (Filer) CIK: 0001018710 (see all company filings)

EIN.: 742704230 | Fiscal Year End: 1231
Type: 10-KT | Act: 34 | File No.: 000-21291 | Film No.: 02580103
SIC: 2834 Pharmaceutical Preparations